[u'tandem bites', ['Olivia Ray'], u'2016-07-29T06:41:22Z', u'As a leading immune research service\nprovider, Creative Biolabs is committed to providing customers the most\ncomprehensive list of BsAb fragments products in the market. Classified by\ntheir size and backbone utilized, Our BsAb fragment products include:\nBi-nanobody, DART, TandAb, BiTE, Tandem scFv-Fc BsAb, Diabody, Triplebody,\nMini-antibody, Minibody, scFv fragments BsAb, Fab fragments BsAb, scFv-Fab\nfragments BsAb, Bispecific intrabody and Tetravalent hcAb. Learn about tandem\nbites.', u'https://figshare.com/articles/tandem_bites/3504917', [u'Biological Engineering'], []]
[u'Bispecific Antibodies', ['Olivia Ray'], u'2016-07-29T06:35:55Z', u'Bispecific antibodies are now\nbeing served as effective therapeutic agents in cancer immunotherapy. Certain\nrecombinant strategies have been developed to synthesize bispecific antibodies,\nwhich include single chain variable fragment (scFv)-derived formats such as\ntandem diabodies, diabodies, DARTs (Dual Affinity Re-Targeting), BiTes\n(bispecific T-cell engager), and , as well as immunoglobulin G(IgG)-based\nformats such as DVD-Ig (Dual Variable Domain antibodies), Triomab, and\ntwo-in-one antibodies.', u'https://figshare.com/articles/Bispecific_Antibodies/3504911', [u'Biotechnology'], []]
[u'Do emergency medicine journals promote trial registration and adherence to reporting guidelines? A systematic review', ['Matthew Sims', 'Nolan Henning', 'Cole Wayant', 'Matt Vassar'], u'2016-07-28T18:50:50Z', u'The objective of this study was to investigate the policies of Emergency Medicine journals concerning guideline adoption and clinical trial registration to understand the extent to which journals are using these mechanisms as a means to improve study quality and reporting.', u'https://figshare.com/articles/Data_Sheet_-_ER_Guidelines_xlsx/3406477', [u'Emergency Medicine'], []]
